Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

42.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Seeing the human behind the sample: How compassion training shaped inner awareness, relationships, and workplace meaning in HIV end-of-life research.

Palliative care and social practice·2026
Same author

Impact of specific ligands and HIV latency reversal agents on estrogen Receptor alpha in CD4+ T cells.

JCI insight·2026
Same author

Single-cell analysis of HIV expression and integration sites reveals robust viral expression across diverse chromatin environments.

Microbiology spectrum·2026
Same author

A screen of chromatin-targeting compounds identifies TAF1 as a novel regulator of HIV latency.

mBio·2026
Same author

Understanding trial designs and acceptability of participation in an HIV vaccine trial with concurrent randomisation to oral pre-exposure prophylaxis in East and Southern Africa: a longitudinal qualitative study.

Trials·2026
Same author

MVA.HIVconsvX vaccination-evoked T cell expansion inversely associates with age in people with HIV-1 on antiretroviral therapy.

The Journal of clinical investigation·2026

Related Experiment Video

Updated: Apr 23, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K

Framing expectations in early HIV cure research.

Karine Dubé1, Gail E Henderson2, David M Margolis1

  • 1Collaboratory of AIDS Researchers for Eradication (CARE), Institute for Global Health and Infectious Diseases (IGHID), The University of North Carolina at Chapel Hill, 120 Mason Farm Road, 2060 Genetic Medicine Building CB 7042, Chapel Hill, NC 27599-7042, USA.

Trends in Microbiology
|October 5, 2014
PubMed
Summary

Managing expectations in HIV cure research is crucial. Using the term "cure experiments" accurately describes these proof-of-concept studies evaluating new methods to reduce HIV-1 reservoirs, without promising medical benefit.

Keywords:
HIV cure researchexpectationsexperimentstrials

More Related Videos

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

10.8K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

5.5K

Related Experiment Videos

Last Updated: Apr 23, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.2K
Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

10.8K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

5.5K

Area of Science:

  • Clinical research communication
  • HIV cure scientific strategy

Background:

  • Effective communication in clinical research is vital for volunteer education.
  • HIV cure research presents unique challenges in managing participant expectations.

Purpose of the Study:

  • To advocate for the use of the term "cure experiments" in HIV cure research.
  • To clarify the nature of these studies as proof-of-concept evaluations.

Main Methods:

  • Analysis of communication strategies in clinical trials.
  • Defining the scope and goals of HIV cure research experiments.

Main Results:

  • The term "cure experiment" accurately reflects the study design.
  • These studies aim to evaluate novel paradigms for reducing persistent HIV-1 reservoirs.
  • There is no expectation of immediate medical benefit for participants.

Conclusions:

  • Employing the term "cure experiment" enhances clarity and manages expectations in HIV cure research.
  • This terminology accurately describes studies focused on proof-of-concept for HIV reservoir reduction.